CPA
VNDA icon

Capital Performance Advisors’s Vanda Pharmaceuticals VNDA Stock Holding History

Capital Performance Advisors’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-303
Closed -$1.42K – 2619
2024
Q3 		$1.42K Buy
+303
New +$1.62K ﹤0.01% 1736

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

Capital Performance Advisors's VNDA Position: Q4 2024 in Review

Capital Performance Advisors sold out of Vanda Pharmaceuticals (VNDA) in Q4 2024, closing a stake of 303 shares — an estimated $1.42K sold.

Capital Performance Advisors first reported a position in VNDA in Q3 2024 and held it in 1 quarter. The position peaked at $1.42K in Q3 2024. 146 funds tracked by Wall St. Rank hold VNDA as of Q4 2024.

  • Capital Performance Advisors reported no remaining Vanda Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 303 Vanda Pharmaceuticals shares in Q4 2024, an estimated $1.42K.
  • Capital Performance Advisors first reported a position in Vanda Pharmaceuticals in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's Vanda Pharmaceuticals position peaked at $1.42K in Q3 2024.
  • 146 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.